secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cullinan Therapeutics, Inc. (CGEM)
CIK:        0001789972
Form:       8-K
Filed at:   2026-08-12T23:35:50+00:00
Accession:  0001193125-26-347400
Event type: other_material
Sentiment:  positive
Materiality: 0.90
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cullinan's zipalertinib combo meets PFS endpoint in Phase 3 REZILIENT3 trial
----------------------------------------------------------------------------

- REZILIENT3 Phase 3 trial (285 patients) met primary endpoint of PFS at planned interim analysis; statistically significant and clinically meaningful improvement.
- Zipalertinib plus platinum-based chemotherapy vs chemo alone in first-line EGFR exon 20 insertion NSCLC; safety manageable.
- Independent Data Monitoring Committee recommended unblinding; trial continues for efficacy/safety monitoring.
- Taiho and Cullinan plan to pursue U.S. FDA approval for the combination in first-line setting pending discussions.
- Full results to be submitted for presentation at an upcoming international medical conference.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1789972/000119312526347400/0001193125-26-347400-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1789972/000119312526347400/cgem-20260812.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-347400

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer